LONG-TERM SURVIVAL AFTER HISTOLOGIC TRANSFORMATION OF LOW-GRADE FOLLICULAR LYMPHOMA

被引:127
作者
YUEN, AR
KAMEL, OW
HALPERN, J
HORNING, SJ
机构
[1] STANFORD UNIV,MED CTR,DEPT MED,DIV ONCOL,STANFORD,CA 94304
[2] STANFORD UNIV,MED CTR,DEPT SURG PATHOL,STANFORD,CA 94304
[3] STANFORD UNIV,MED CTR,DEPT HLTH RES,STANFORD,CA 94304
[4] STANFORD UNIV,MED CTR,DEPT POLICY,STANFORD,CA 94304
关键词
D O I
10.1200/JCO.1995.13.7.1726
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To describe the course of patients following histologic transformation (HT) from low-grade follicular lymphoma to intermediate- or high-grade non-Hodgkin's lymphoma. Patients and Methods: Patients were identified from data bases in the Division of Oncology and the Deportment of Surgical Pathology. HT was defined as the conversion of a follicular small cleaved-cell or follicular mixed small cleaved-cell and large-cell lymphoma to a diffuse large-cell, diffuse mixed small cleaved-cell and large-cell or any high-grade lymphoma. Results: We analyzed the clinical course of 74 low-grade lymphoma patients with histologically proven transformation occurring from 1965 to 1988. The median time from diagnosis to HT was 66 months, acid the median age at HT was 58 years. The median duration of survival after transformation was 22 months. Anatomic extent of disease at HT (limited v extensive, P = .01), prior chemotherapy (none v any, P = .01), and response to therapy (complete v partial or none, P = .005) at time of HT were identified as significant predictors of survival after HT in backward-selection Cox regression analysis. Thirty patients attained a complete response to therapy at HT. They had a median survival duration of 81 months after HT. Conclusion: A subset of patients with HT from low-grade follicular lymphoma to intermediate- or high-grade lymphoma enjoys relatively long-term survival, Patients with limited disease and no previous exposure to chemotherapy have the most favorable prognosis,
引用
收藏
页码:1726 / 1733
页数:8
相关论文
共 48 条
  • [1] HISTOLOGIC CONVERSION IN THE NON-HODGKINS LYMPHOMAS
    ACKER, B
    HOPPE, RT
    COLBY, TV
    COX, RS
    KAPLAN, HS
    ROSENBERG, SA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (01) : 11 - 16
  • [2] CLINICAL-FEATURES AND PROGNOSIS OF FOLLICULAR LARGE-CELL LYMPHOMA - A REPORT FROM THE NEBRASKA-LYMPHOMA-STUDY-GROUP
    ANDERSON, JR
    VOSE, JM
    BIERMAN, PJ
    WEISENBURGER, DD
    SANGER, WG
    PIERSON, J
    BAST, M
    ARMITAGE, JO
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (02) : 218 - 224
  • [3] ARMITAGE JO, 1981, CANCER TREAT REP, V65, P413
  • [4] EXPRESSION OF P-GLYCOPROTEIN AND GLUTATHIONE-S-TRANSFERASE IN RECURRENT LYMPHOMAS - THE POSSIBLE ROLE OF EPSTEIN-BARR-VIRUS, IMMUNOPHENOTYPES, AND OTHER PREDISPOSING FACTORS
    CHENG, AL
    SU, IJ
    CHEN, YC
    LEE, TC
    WANG, CH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (01) : 109 - 115
  • [5] COX DR, 1972, J R STAT SOC B, V34, P187
  • [6] CULLEN MH, 1979, CANCER, V44, P645, DOI 10.1002/1097-0142(197908)44:2<645::AID-CNCR2820440234>3.0.CO
  • [7] 2-Y
  • [8] ERSBOLL J, 1989, EUR J HAEMATOL, V42, P155
  • [9] FREEDMAN AS, 1991, BLOOD, V77, P2524
  • [10] GARVIN AJ, 1983, CANCER-AM CANCER SOC, V52, P393, DOI 10.1002/1097-0142(19830801)52:3<393::AID-CNCR2820520302>3.0.CO